JPMorgan initiated coverage of Immunovant with an Overweight rating and $51 price target. Immunovant is one of the key anti-FcRn players in autoimmune disease, the analyst tells investors in a research note. The firm thinks the company’s longer-term, de-risked outlook holds opportunities given the multiple clinical and strategic catalysts by the first half of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMVT:
- Wolfe starts Immunovant at Outperform, says excited about catalyst path
- Immunovant initiated with an Outperform at Wolfe Research
- Immunovant remains top pick at Citi after year-to-date selloff
- Immunovant, Inc. Is Worried About This – Should You Be Worried Too?
- Immunovant options imply 3.5% move in share price post-earnings
